UBS analyst Dan Leonard lowered the firm’s price target on Fulgent Genetics (FLGT) to $20 from $27 and keeps a Neutral rating on the shares.
Fulgent Genetics ( NASDAQ:FLGT ) Full Year 2024 Results Key Financial Results Revenue: US$283.5m (down 2.0% from FY... EL MONTE, Calif., February 28, 2025--Fulgent Genetics, Inc. (NASDAQ ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Fulgent Genetics (FLGT) to $16 from $22 following quarterly results.
Fulgent Genetics (($FLGT)) has held its Q4 earnings call. Read on for the main highlights of the call. Fulgent Genetics’ recent earnings call ...
Proficio Capital Partners LLC bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the ...